Frontier Pharma Chronic, Acute and Neuropathic Pain Frontier Pharma Chronic, Acute and Neuropathic Pai | 页面 4

2.1 Substantial Unmet Needs Remain in Core Therapy Types 4
2.2 Highly Diversified Range of Innovative Programs in Early Pipeline 4
2.3 Rich Pipeline Landscape with Numerous Investment Opportunities 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Development Remains Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8
Read Complete Report With TOC @ http://www.radiantinsights.com/research/frontier-
pharma-chronic-acute-and-neuropathic-pain-gpcr-and-nerve-growth
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.1.1 Chronic and Neuropathic Pain 10
4.1.2 Disease Pathophysiology 11
4.1.3 Diagnosis 14
4.1.4 Treatment Options 15
4.2 Overview of Marketed Products for Pain 15
4.2.1 Analgesic Product Categories 16
4.2.2 Molecular Type Analysis 17
4.2.3 Current Unmet Needs 18
5 Assessment of Pipeline Product Innovation in Chronic, Acute and Neuropathic Pain 20
5.1 Pain Pipeline by Molecule Type, Stage of Development and Molecular Target 20
Follow Us: